Dr. Andrii Buvailo is a pharmaceutical industry analyst, tech scout and writer with a focus on
artificial intelligence (AI) in drug discovery and biotech, digital transformation of pharma industry,
and the advent of novel therapeutic modalities.
Andrii’s reports touch upon disruptive biotech startups, venture capital deals, drug discovery
IPOs and platform companies. His articles were
published on Forbes,
and market research reports were referenced by some of the leading organizations (e.g. Deloitte).
Andrii is an ex-Enamine veteran, having served for the company as
Director of E-commerce and Marketing for more
than 8 years. Enamine is a global supplier of fine chemicals and compound libraries for the
pharmaceutical industry.
Before venturing into the pharmaceutical industry and media entrepreneurship, Andrii used to work as a
scientist.
He holds PhD in Physical Chemistry, and has research experience in bioinorganic and supramolecular
chemistry, thin polymer films, nanomaterials, and sensors.
A new five-year commercial agreement and go-to-market collaboration aims to merge 1910 Genetics' comprehensive computational and biological data with Microsoft’s HPC …
(Updated: 24.02.2024) Molecular mechanics (MM) is a traditional computational approach when it comes to modeling in synthetic organic chemistry, medicinal …
Receptor.AI, a London-based drug discovery company and NVIDIA Inception member, has successfully integrated NVIDIA BioNeMo cloud APIs with their end-to-end …
Neuralink, the neurotechnology firm led by entrepreneur Elon Musk, has reportedly achieved a significant milestone by successfully implanting its first …
Data is king in modern biopharmaceutical research, and ability to generate massive amounts of quality biomedical data represents a tremendous research …
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.